Innovative platforms for development of TCR-T cell therapies against novel tumor targets: Triple negative breast cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
For permission requests, please contact NEJM Reprints at [email protected] Select the format you want to export the citation of this publication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback